Background/Aims: Supplementation with antioxidants is of special interest in preventing or delaying the development and progression of age-related macular degeneration (AMD). This investigation aimed to assess the effect of α- lipoic acid (LA) on serum lipids, serum malondialdehyde (MDA) and superoxide dismutase (SOD) in patients with AMD. Methods: A total of 62 patients (50–75 years old) with early and intermediate dry form of AMD were randomly assigned to two groups, i.e. LA administration (n = 32) and placebo (n = 30). The levels of serum lipids and MDA and SOD activity were measured before and after LA and placebo intervention. Results: Compared with the parameters at baseline, serum total cholesterol (CHO), triglyceride and high- and low-density lipoprotein CHO (HDL and LDL) levels were not significantly different after LA and placebo intervention. There was a slight but statistically nonsignificant decrease in serum MDA levels and a statistically significant increase in serum SOD activity after LA intervention. There were no statistically significant differences in serum MDA levels or SOD activity after placebo intervention. Conclusion: The apparent increase in SOD activity caused by LA supplementation indicates that LA may have a possible preventive effect in the development of AMD through an antioxidant mechanism.

Keywords:
(R)-α-lipoic acid, Age-related macular degeneration, Serum lipids, Malondialdehyde, Superoxide dismutase
1.
Feng Z, Liu Z, Li X, Jia H, Sun L, Tian C, Jia L, Liu J: α-Tocopherol is an effective phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J Nutr Biochem 2010;21:1222–1231.
2.
Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco Gabrieli C: Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging 2006;27:983–993.
3.
Lee AY, Brantley MA Jr: CFH and LOC387715/ARMS2 genotypes and antioxidants and zinc therapy for age-related macular degeneration. Pharmacogenomics 2008;9:1547–1550.
4.
Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, betacarotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol 2001;119:1417–1436.
5.
Packer L, Roy S, Sen CK: Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997;38:79–101.
6.
Biewenga GP, Haenen GR, Bast A: The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997;29:315–331.
7.
Huk-Kolega H, Skibska B, Kleniewska P, Piechota A, Michalski Ł, Goraca A: Role of lipoic acid in health and disease. Pol Merkur Lekarski 2011;31:183–185.
8.
Liu J, Ames BN: Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer’s disease, and Parkinson’s disease. Nutr Neurosci 2005;8:67–89.
9.
de Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK: The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract 2011;92:253–260.
10.
Kamenova P: Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 2006;5:251–258.
11.
Jia L, Liu Z, Sun L, Miller SS, Ames BN, Cotman CW, Liu J: Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: protection by (R)-α-lipoic acid. Invest Ophthalmol Vis Sci 2007;48:399–448.
12.
Jager RD, Mieler WF, Miller JW: Age-related macular degeneration. N Engl J Med 2008;358:2606–2617.
13.
Jain SK: Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochim Biophys Acta 1988;937:205–210.
14.
Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E, Saraymen R, Üstdal M: Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006;220:12–16.
15.
Evereklioglu C, Er H, Doganay S, Cekmen M, Turkoz Y, Otlu B, Ozerol E: Nitric oxide and lipid peroxidation are increased and associated with decreased antioxidant enzyme activities in patients with age-related macular degeneration. Doc Ophthalmol 2003;106:129–136.
16.
Totan Y, Cekiç O, Borazan M, Uz E, Sögüt S, Akyol O: Plasma malondialdehyde and nitric oxide levels in age related macular degeneration. Br J Ophthalmol 2001;85:1426–1428.
17.
Tate DJ Jr, Miceli MV, Newsome DA: Phagocytosis and H2O2 induce catalase and metallothionein gene expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1995;36:1271–1279.
18.
Jin GF, Hurst JS, Godley BF: Rod outer segments mediate mitochondrial DNA damage and apoptosis in human retinal pigment epithelium. Curr Eye Res 2001;23:11–19.
19.
Srivastava S, Chandra A, Bhatnagar A, Srivastava SK, Ansari NH: Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 1995;217:741–746.
20.
Gaillard ER, Atherton SJ, Eldred G, Dillon J: Photophysical studies on human retinal lipofuscin. Photochem Photobiol 1995;61:448–453.
21.
Justilien V, Pang JJ, Renganathan K, Zhan X, Crabb JW, Kim SR, Sparrow JR, Hauswirth WW, Lewin AS: SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci 2007;48:4407–4420.
22.
Kasahara E, Lin LR, Ho YS, Reddy VN: SOD2 protects against oxidation-induced apoptosis in mouse retinal pigment epithelium: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 2005;46:3426–3434.
23.
Johnsen-Soriano S, Garcia-Pous M, Arnal E, Sancho-Tello M, Garcia-Delpech S, Miranda M, Bosch-Morell F, Diaz-Llopis M, Navea A, Romero FJ: Early lipoic acid intake protects retina of diabetic mice. Free Radic Res 2008;42:613–617.
24.
Wang W, Connor SL, Johnson EJ, Klein ML, Hughes S, Connor WE: Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration. Am J Clin Nutr 2007;85:762–769.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.